ClinicalTrials.gg
CompletedNCT06694389Updated Dec 2, 2025

Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age

A Phase 3 interventional study of mRNA-1083 and Placebo in COVID-19 and Influenza, sponsored by ModernaTX, Inc.. Completed at 44 sites in 3 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Nov 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,457
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in COVID-19 by Moderna, Inc. — 3 open to participants now, 6 under way, none of them phase 3. COVID-19 · Moderna, Inc..

Enrollment
8th of 22
2,457 · median 988
Started
2024
with 2 others
Phase 3
6 of 34
none open now
Registered
29th of 34
by date

Among the 34 studies in COVID-19 by Moderna, Inc., this one is the 8th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2024, is one of 6 in phase 3, and was the 29th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 34 studies in COVID-19 by Moderna, Inc. are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in COVID-19 by Moderna, Inc., or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea).

03

Conditions studied

  • COVID-19
  • Influenza

Keywords

  • Influenza
  • COVID-19
  • Messenger RNA
  • Moderna
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Medically stable adults ≥50 years of age at the time of consent (Screening/Day 1 Visit).
  • A participant who could become pregnant is eligible to participate if the following is met:

    • Not pregnant or breast/chestfeeding, and is using a method that is highly effective for at least 90 days after the study intervention administration and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period.
    • Have a negative highly sensitive pregnancy test (urine) as required by local regulations at Screening/Day 1 Visit, before the study intervention.
  • Participants who can produce sperm are eligible to participate if they agree to the following for at least 90 days after the study intervention administration:

    • Refrain from donating sperm.
    • Either be abstinent from reproductive sexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent or must agree to use an external condom with a person who could become pregnant partner use of an additional highly effective contraceptive method with a failure rate of \<1% per year when having sexual intercourse.
  • Agree to use an external condom when engaging in any activity that allows for passage of ejaculate to another person.
  • Received ≥2 COVID-19 vaccines and the last COVID-19 vaccine was ≥150 days prior to Day 1

Key Exclusion Criteria:

  • History of a diagnosis or condition that, in the judgment of the Investigator, is clinically unstable or may affect participant safety, assessment of study endpoints, assessment of immune response, or adherence to study procedures.
  • Any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results.
  • Known history of SARS-CoV-2 infection within 150 days prior to Day 1.
  • Tested positive for influenza by local health authority-approved testing methods ≤150 days prior to Day 1.
  • Received at ≥10 mg/day of prednisone or equivalent for >14 days in total within 90 days prior to Day 1 or is anticipating the need for corticosteroids at any time during the study. Inhaled nasal and topical steroids are allowed.
  • Received systemic treatment, including long-acting biological therapies that affect immune responses (for example, infliximab), within 180 days prior to Day 1 or plans to do so during the study.
  • Received or plans to receive any vaccine authorized or approved by a local health agency ≤28 days prior to study injections or plans to receive a vaccine authorized or approved by a local health agency within 28 days after the study injections.
  • Received a seasonal influenza vaccine ≤150 days prior to Day 1.
  • Treated with antiviral therapies for influenza (for example, Tamiflu®) ≤150 days prior to Day 1.
  • Has had close contact with someone with laboratory-confirmed influenza infection or with someone who has been treated with antiviral therapies for influenza (for example, Tamiflu) within 5 days prior to Day 1
  • Has had close contact to someone with COVID-19 as defined by the Centers for Disease Control and Prevention (CDC) in the past 10 days prior to Day 1.
  • Has donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit/Day 1 or plans to donate blood products during the study.
  • Reported history of anaphylaxis or severe reaction after receipt of any mRNA or influenza vaccines or any components of the mRNA or influenza vaccines, including egg protein.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,457 participants (actual)

Study arms

  • Experimental
    mRNA-1083 and Placebo

    Participants 50 years of age and older will receive mRNA-1083 by intramuscular (IM) injection and placebo by subcutaneous (SC) or IM injection administered on Day 1.

    Biological: mRNA-1083 · Other: Placebo

  • Active comparator
    Licensed influenza vaccine + SARS-CoV-2 vaccine

    Participants of age 50 years and older will receive licensed influenza vaccine by SC or IM injection and SARS-CoV-2 vaccine by IM injection administered on Day 1.

    Biological: Licensed Influenza Vaccine · Biological: SARS-CoV-2 Vaccine

Interventions

  • BiologicalmRNA-1083

    Suspension for injection

  • OtherPlacebo

    0.9% sodium chloride suspension for injection

  • BiologicalLicensed Influenza Vaccine

    Aqueous injectable (SC) or suspension for injection (IM)

    Also known as: Influenza HA, Biken, and, Fluarix tetra

  • BiologicalSARS-CoV-2 Vaccine

    Suspension for injection

    Also known as: mRNA-1273

06

What researchers measure

Primary outcomes

  1. Geometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) Assay

    Time frame: Day 29

  2. GM Level of Antibodies for SARS-CoV-2, as Measured by Pseudovirus Neutralization Assay (PsVNA)

    Time frame: Day 29

  3. Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

    Time frame: Day 1 through 7 days after study injection

  4. Number of Participants With Unsolicited Adverse Events (AEs)

    Time frame: Day 1 through 28 days after study injection

  5. Number of Participants With Medically Attended Adverse Events (MAAEs)

    Time frame: Day 1 though Day 181

  6. Number of Participants With Adverse Events of Special Interest (AESIs)

    Time frame: Day 1 though Day 181

  7. Number of Participants With Serious Adverse Events (SAEs)

    Time frame: Day 1 through Day 181

  8. Number of Participants With AEs Leading to Discontinuation

    Time frame: Day 1 through Day 181

Secondary outcomes

  1. Influenza: Percentage of Participants with Seroconversion, as Measured by HAI Assay

    Seroconversion is defined as a Day 29 post-injection level ≥1:40 if baseline is \<1:10 or a 4-fold or greater rise if baseline is ≥1:10 in anti-HA antibodies measured by HAI assay.

    Time frame: Day 29

  2. SARS-CoV-2: Percentage of Participants with Seroresponse, as Measured by PsVNA

    Seroresponse is defined as a Day 29 post-injection level ≥4-fold if baseline is ≥lower limit of quantification (LLOQ) or ≥4\*LLOQ if baseline titer is \<LLOQ in neutralizing antibody (nAb) values measured by PsVNA.

    Time frame: Day 29

  3. Geometric Mean Fold-Rise (GMFR) of Antibodies for Influenza, as Measured by HAI Assay

    Time frame: Day 1, Day 29

  4. GMFR of Antibodies for SARS-CoV-2, as Measured by PsVNA

    Time frame: Day 1, Day 29

07

Study locations

44 sites
  • Public Health Association.Inc.
    Nagoya, Aichi-ken 453-0804, Japan
  • Daido Clinic
    Nagoya, Aichi-ken 457-8511, Japan
  • Tenjin Sogo Clinic
    Fukuoka, Fukuoka 810-0021, Japan
  • PS Clinic - Internal medicine
    Fukuoka, Fukuoka 812-0025, Japan
  • Fukuoka Heartnet Hospital
    Fukuoka, Fukuoka 819-0002, Japan
  • Medical Coporation of Yamazaki Neurotology, Rhinolaryngology Clinical
    Sapporo, Hokkaido 060-0011, Japan
  • Motomachi Takatsuka Naika Clinic - Internal Medicine
    Yokohama, Kanagawa 231-0023, Japan
  • Sakurajyuji Medical Corporation Medimesse Sakurajyuji Clinic
    Kumamoto, Kumamoto 860-0833, Japan
  • Nishi-Kumamoto Hospital
    Kumamoto, Kumamoto 861-4157, Japan
  • Sato Hospital
    Osaki-shi, Miyagi 989-6143, Japan
  • Yokoi Medicine Clinic
    Mino, Osaka 562-0003, Japan
  • Shinwakai Adachi Kyosai Hospital - Internal Medicine
    Adachi-ku, Tokyo 120-0022, Japan
  • Dojinkinenkai Meiwa Hospital
    Chiyoda-ku, Tokyo 101-0041, Japan
  • Nihonbashi Sakura Clinic
    Chuo-ku, Tokyo 103-0025, Japan
  • Tokyo center clinic - Internal medicine
    Chuo-ku, Tokyo 103-0027, Japan
  • Medical Corporation Asbo Tokyo Asbo Clinic
    Chuo-ku, Tokyo 104-0031, Japan
  • New Medical Research System Clinic
    Hachioji-shi, Tokyo 192-0046, Japan
  • Shimamura Memorial Hospital
    Nerima City, Tokyo 177-0051, Japan
  • Denenchofu Family Clinic
    Ōta-ku, Tokyo 145-0071, Japan
  • Hillside Clinic Jingumae
    Shibuya-ku, Tokyo 150-0001, Japan
  • Clinical Research Tokyo Hospital - Clinical Research Center
    Shinjuku, Tokyo 160-0004, Japan
  • Higashi-Shinjuku Clinic - Internal Medicine
    Shinjuku, Tokyo 169-0072, Japan
  • Shinei Medical Healthcare Clinic
    Suginami, Tokyo 166-0003, Japan
  • Souseikai Sumida Hospital
    Sumida-Ku, Tokyo 130-0004, Japan
  • Seishukai Clinic
    Taito-ku, Tokyo 111-0036, Japan
  • Metropolitan Clinic - Internal Medicine
    Toshima-ku, Tokyo 171-0021, Japan
  • Korea University Ansan Hospital
    Ansan-si, 15355, South Korea
  • Kyungpook National University Hospital - Infectious Diseases
    Daegu, South Korea
  • Chonnam National University Hospital - Allergology
    Gwangju, 61469, South Korea
  • Inha University Hospital
    Incheon, 22332, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, 13620, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
  • Hallym University Kangnam Sacred Heart Hospital
    Seoul, 07441, South Korea
  • Korea University Guro Hospital
    Seoul, 08308, South Korea
  • Ajou University Hospital
    Suwon, 16499, South Korea
  • Yonsei University, Wonju Severance Christian Hospital
    Wŏnju, South Korea
  • Kaohsiung Medical University - Chung-Ho Memorial Hospital
    Kaohsiung City, 807, Taiwan
  • Kaohsiung Veterans General Hospital
    Kaohsiung City, 813 404, Taiwan
  • Kuang Tien General Hospital - Dajia
    Taichung, 437, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
  • Taipei Medical University - Taipei Medical University Hospital
    Taipei, 110, Taiwan
  • Tri-Service General Hospital - Neihu Branch - Infectious Diseases
    Taipei, 114, Taiwan
  • Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital
    Taoyuan, 333, Taiwan
08

References and documents

Publications

  • Kostanyan L, Fukase H, Rumyantsev A, Hashizume K, Osibajo S, Kogawara O. Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged >/=50 years in Japan. Vaccine. 2026 Jul 30;88:128961. doi: 10.1016/j.vaccine.2026.128961. Online ahead of print. PubMed 42531981 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Nov 2025, 11 months.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 11 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2024
First posted
Nov 19, 2024
StartActual
Nov 18, 2024
Primary completionActual
Nov 17, 2025
CompletionActual
Nov 17, 2025
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06694389
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Nov 19, 2024
Start date
Nov 18, 2024
Primary completion
Nov 17, 2025
Completion
Nov 17, 2025
Last update
Dec 2, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MRNA-1083

Start the discussion